公开(公告)号：US20210047434A1

公开(公告)日：2021-02-18

申请号：US17011433

申请日：2020-09-03

Applicant: Amgen Inc.

Inventor： Joyce Chi Yee Chan ,  John P. Gibbs ,  Clapton S. Dias ,  Scott Wasserman ,  Robert Andrew Donald Scott ,  Christi L. Clogston ,  Timothy David Osslund ,  Evan A. Stein

IPC: C07K16/40 ,  A61K39/395

Abstract: The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.

公开(公告)号：US20160060337A1

公开(公告)日：2016-03-03

申请号：US14776222

申请日：2014-02-25

Applicant: AMGEN INC.

Inventor： John P. Gibbs ,  Wayne Tsuji ,  Wei-Jian Pan

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/541 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/90

Abstract: The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis.

Abstract translation: 本发明涉及治疗牛皮癣的产品和方法。 该产品涉及抑制天然人IL-23同时保护IL-12的抗体。 一个例子描述了1期随机，双盲，安慰剂对照，上升单剂量研究，以评估健康受试者和中度受试者的抗IL-23抗体（AMG 139）的安全性，耐受性，药代动力学和药效学 到严重的牛皮癣。